Voyager Therapeutics Inc - Understand $vygr stock

$VYGR Market Cap: $372.5 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$163.8M

TTM

Gross Margin

Net Earnings

$25.88M

TTM

Current Assets

$373.4M

Q3 2024

Current Liabilities

$44.21M

Q3 2024

Current Ratio

844.7%

Q3 2024

Total Assets

$426.0M

Q3 2024

Total Liabilities

$95.73M

Q3 2024

Book Value

$330.3M

Q3 2024

Cash

$112.5M

Q3 2024

P/E

14.39

Nov 12, 2024 EST

Free Cash Flow

-$436.0K

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$250.0M	$40.91M	$37.42M	$171.1M	$104.4M	$7.619M	$10.14M	$14.20M	$17.30M	$0.00	$0.00
YoY Change	511.16%	9.33%	-78.14%	63.93%	1270.14%	-24.82%	-28.63%	-17.92%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$250.0M	$40.91M	$37.42M	$171.1M	$104.4M	$7.619M	$10.14M	$14.20M	$17.30M	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$35.82M	$30.98M	$37.25M	$35.00M	$36.30M	$33.80M	$19.70M	$13.30M	$9.900M	$5.500M	$1.500M
YoY Change	15.63%	-16.82%	6.42%	-3.58%	7.4%	71.57%	48.12%	34.34%	80.0%	266.67%
% of Gross Profit
Research & Development	$92.17M	$60.76M	$73.79M	$108.8M	$119.7M	$64.91M	$62.26M	$42.20M	$27.70M	$8.900M	$2.300M
YoY Change	51.69%	-17.65%	-32.15%	-9.17%	84.48%	4.25%	47.54%	52.35%	211.24%	286.96%
% of Gross Profit
Depreciation & Amortization	$4.400M	$6.200M	$5.200M	$3.800M	$2.800M	$2.100M	$1.600M	$610.0K	$600.0K	$180.0K	$0.00
YoY Change	-29.03%	19.23%	36.84%	35.71%	33.33%	31.25%	162.3%	1.67%	233.33%
% of Gross Profit
Operating Expenses	$128.0M	$91.74M	$111.0M	$143.7M	$156.1M	$98.71M	$82.00M	$55.50M	$37.60M	$14.40M	$3.800M
YoY Change	39.51%	-17.37%	-22.76%	-7.9%	58.1%	20.39%	47.74%	47.61%	161.11%	278.95%
Operating Profit	$122.0M	-$50.84M	-$73.62M	$27.38M	-$51.68M	-$91.10M	-$71.86M
YoY Change	-340.01%	-30.94%	-368.84%	-152.99%	-43.27%	26.76%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	$11.72M	$1.792M	-$390.0K	$1.659M	$6.457M	$3.310M	$1.227M	$1.000M	$300.0K	$0.00	-$100.0K
YoY Change	554.07%	-559.49%	-123.51%	-74.31%	95.08%	169.76%	22.7%	233.33%		-100.0%
% of Operating Profit	9.61%			6.06%
Other Income/Expense, Net	$11.72M	$4.445M	$2.421M	$9.357M	$8.082M	$2.627M	$1.165M	$200.0K	-$9.800M	-$1.900M	$0.00
YoY Change	163.76%	83.6%	-74.13%	15.78%	207.65%	125.49%	482.5%	-102.04%	415.79%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	$133.7M	-$46.39M	-$71.20M	$36.74M	-$43.60M	-$88.47M	-$70.70M	-$40.10M	-$29.70M	-$16.30M	-$3.800M
YoY Change	-388.28%	-34.84%	-293.78%	-184.27%	-50.72%	25.14%	76.3%	35.02%	82.21%	328.95%
Income Tax	$1.408M	$16.00K		$0.00	$0.00	-$180.0K	$0.00	$100.0K
% Of Pretax Income	1.05%			0.0%
Net Earnings	$132.3M	-$46.41M	-$71.20M	$36.74M	-$43.60M	-$88.29M	-$70.70M	-$40.20M	-$29.70M	-$16.30M	-$3.800M
YoY Change	-385.14%	-34.82%	-293.78%	-184.27%	-50.62%	24.88%	75.87%	35.35%	82.21%	328.95%
Net Earnings / Revenue	52.93%	-113.45%	-190.29%	21.47%	-41.76%	-1158.79%	-697.56%	-283.1%	-171.68%
Basic Earnings Per Share	$3.08	-$1.21	-$1.89	$0.99	-$1.21	-$2.75
Diluted Earnings Per Share	$2.97	-$1.21	-$1.89	$0.98	-$1.21	-$2.75	-$2.638M	-$1.589M	-$1.156M	-$634.2K	-$147.9K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$230.9M	$118.8M	$132.5M	$181.1M	$281.5M	$155.8M	$169.1M	$174.4M	$194.3M	$7.000M	$100.0K
YoY Change	94.26%	-10.33%	-26.81%	-35.67%	80.68%	-7.87%	-3.04%	-10.24%	2675.71%	6900.0%
Cash & Equivalents	$68.80M	$98.96M	$117.4M	$104.4M	$86.00M	$46.90M	$31.50M	$36.60M	$31.30M	$7.000M	$100.0K
Short-Term Investments	$162.1M	$19.89M	$15.11M	$76.70M	$195.5M	$108.9M	$137.5M	$137.8M	$163.0M	$0.00	$0.00
Other Short-Term Assets	$4.354M	$5.012M	$3.411M	$8.500M	$4.200M	$6.500M	$2.700M	$4.000M	$1.200M	$1.300M	$0.00
YoY Change	-13.13%	46.94%	-59.87%	102.38%	-35.38%	140.74%	-32.5%	233.33%	-7.69%
Inventory
Prepaid Expenses
Receivables	$83.49M	$257.0K	$732.0K	$8.000M	$18.50M
Other Receivables	$964.0K	$382.0K	$16.00K	$100.0K	$500.0K
Total Short-Term Assets	$319.7M	$124.5M	$136.7M	$197.8M	$304.7M	$162.5M	$171.8M	$178.8M	$195.9M	$8.400M	$100.0K
YoY Change	156.78%	-8.92%	-30.89%	-35.08%	87.51%	-5.41%	-3.91%	-8.73%	2232.14%	8300.0%
Property, Plant & Equipment	$30.00M	$33.34M	$55.38M	$61.50M	$46.50M	$12.80M	$10.30M	$7.900M	$3.200M	$2.800M	$0.00
YoY Change	-10.01%	-39.79%	-9.95%	32.26%	263.28%	24.27%	30.38%	146.88%	14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments				$0.00	$1.900M	$600.0K	$1.100M	$1.400M	$30.00M	$0.00	$0.00
YoY Change				-100.0%	216.67%	-45.45%	-21.43%	-95.33%
Other Assets	$1.593M	$1.515M	$1.779M	$2.300M	$1.700M	$1.100M	$1.300M	$1.500M	$300.0K	$300.0K	$0.00
YoY Change	5.15%	-14.84%	-22.65%	35.29%	54.55%	-15.38%	-13.33%	400.0%	0.0%
Total Long-Term Assets	$31.60M	$34.86M	$57.16M	$63.80M	$50.10M	$14.50M	$12.70M	$10.80M	$33.60M	$3.100M	$0.00
YoY Change	-9.35%	-39.02%	-10.41%	27.35%	245.52%	14.17%	17.59%	-67.86%	983.87%
Total Assets	$351.3M	$159.4M	$193.9M	$261.6M	$354.8M	$177.0M	$184.5M	$189.6M	$229.5M	$11.50M	$100.0K
YoY Change
Accounts Payable	$1.604M	$2.566M	$574.0K	$600.0K	$4.100M	$1.000M	$1.000M	$600.0K	$600.0K	$1.600M	$1.000M
YoY Change	-37.49%	347.04%	-4.33%	-85.37%	310.0%	0.0%	66.67%	0.0%	-62.5%	60.0%
Accrued Expenses	$20.02M	$10.65M	$19.80M	$18.40M	$24.70M	$9.800M	$11.50M	$6.500M	$3.400M	$600.0K	$100.0K
YoY Change	88.04%	-46.22%	7.6%	-25.51%	152.04%	-14.78%	76.92%	91.18%	466.67%	500.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.900M
YoY Change										-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$64.51M	$72.59M	$50.98M	$26.80M	$76.00M	$31.70M	$15.90M	$13.80M	$23.90M	$2.500M	$4.000M
YoY Change	-11.13%	42.39%	90.23%	-64.74%	139.75%	99.37%	15.22%	-42.26%	856.0%	-37.5%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$6.300M	$0.00
YoY Change									-100.0%
Other Long-Term Liabilities	$50.45M	$27.75M	$47.82M	$80.50M	$179.2M	$98.90M	$34.50M	$39.80M	$36.50M	$1.600M	$0.00
YoY Change	81.85%	-41.98%	-40.6%	-55.08%	81.19%	186.67%	-13.32%	9.04%	2181.25%
Total Long-Term Liabilities	$50.45M	$27.75M	$47.82M	$80.50M	$179.2M	$98.90M	$34.50M	$39.80M	$36.50M	$7.900M	$0.00
YoY Change	81.85%	-41.98%	-40.6%	-55.08%	81.19%	186.67%	-13.32%	9.04%	362.03%
Total Liabilities	$115.0M	$100.3M	$98.80M	$107.3M	$255.2M	$130.6M	$50.40M	$53.60M	$60.40M	$10.30M	$4.000M
YoY Change	14.58%	1.55%	-7.92%	-57.95%	95.41%	159.13%	-5.97%	-11.26%	486.41%	157.5%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018
Basic Shares Outstanding	43.02M	38.36M	37.67M	37.13M	35.90M	32.07M
Diluted Shares Outstanding	44.57M	38.36M	37.67M	37.35M	35.90M	32.07M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $372.46 Million

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Industry: Biological Products, (No Diagnostic Substances) Peers: 89Bio Inc Evelo Biosciences, Inc. LianBio Cartesian Therapeutics Inc Summit Therapeutics Inc Vaxxinity Inc